Clinical Trial Detail

NCT ID NCT03470922
Title A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Nivolumab + Relatlimab

Nivolumab

Age Groups: child adult senior

No variant requirements are available.